面向个性化抗凝药:心脏置换患者早期华法林反应的临床预测因素
Rania Abdel-Latif1,2, Shaban Mohammed3, Tamer Abdalghafoor4
1Qatar Genome Program, Qatar Precision Health Institute, Qatar Foundation, Doha 5825, Qatar.
Biomedicines
|February 27, 2026
概括
假体门位置,女性性别和基线INR影响心脏门置换后的华法林敏感性. 在这些患者中,早期的华法林管理需要个性化的剂量策略,以获得最佳的结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗信息学 医疗信息学
背景情况:
- 华法林是机械心脏门置换 (HVR) 患者的标准抗凝剂.
- 由于其狭窄的治疗指数和患者间的可变性,早期华法林管理具有挑战性.
- 关于假体门位置如何影响华法林敏感性的证据有限.
研究的目的:
- 评估假肢位置和临床因素对HVR患者早期华法林反应的影响.
- 开发一个用于指导HVR患者初始华法林剂量的预测模型.
主要方法:
- 对310名接受机械大动脉, mitra或双置换的成年患者进行了回顾性研究.
- 华法林在术后24小时内开始使用,并进行三天的监测.
- 分析了每日华法林剂量,INR水平,治疗性INR达到,INR超标,以及3日华法林剂量指数 (WDI3). 使用了多变量回归和LASSO建模.
主要成果:
- 与大动脉或双组相比,米特拉接收者需要较低的华法林剂量,但INR超标率较高.
- 女性性别和更高的基线INR与增加的华法林敏感性有关.
- 中心/双位置预测敏感性降低;只有50%的患者在第3天达到治疗INR.
结论:
- 假体的位置,患者的性别和基线INR显著影响早期的术后华法林反应.
- 应将临床因素纳入剂量算法,以优化HVR患者的初始华法林管理.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis IV: Nursing Management
320
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
320
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288


